Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Friedrich Miescher Institute For Biomedical Research has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners across 4 art units, showing that each matter is handled through a separate examination channel.
DHAR, MATASHA is the busiest examiner, with 1 pending matter. Counsel should maintain consistent scientific terminology and specification support across the portfolio while adapting claim arguments to the distinct examiner and art-unit records.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DHAR, MATASHA | 1 | 43.5% | +44.8% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| HAMMELL, NEIL P | 1 | 34.6% | +43.0% |
| HILL, KEVIN KAI | 1 | 36.0% | +33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756106 | PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN AGMAT-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | HILL, KEVIN KAI | 141d overdue |
| 18255296 | USE OF A COMBINATION OF AN ORPHAN MOTIF AND CPG DENSITY TO CONTROL EXPRESSION OF A HETEROLOGOUS TRANSGENE | CASH, KAILEY ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756106 | PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN AGMAT-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | HILL, KEVIN KAI | 141d overdue |
| 18729674 | PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | DHAR, MATASHA | — |
| 18255296 | USE OF A COMBINATION OF AN ORPHAN MOTIF AND CPG DENSITY TO CONTROL EXPRESSION OF A HETEROLOGOUS TRANSGENE | CASH, KAILEY ELIZABETH | — |
| 17996276 | USE OF AN ORPHAN MOTIF TO INCREASE EXPRESSION OF A HETEROLOGOUS TRANSGENE | HAMMELL, NEIL P | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1683 | 1 |
| 1681 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729674 | PROMOTER FOR THE EXPRESSION OF GENES IN PARTICULAR EGR2-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | DHAR, MATASHA | 1632 | §112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18255296 | USE OF A COMBINATION OF AN ORPHAN MOTIF AND CPG DENSITY TO CONTROL EXPRESSION OF A HETEROLOGOUS TRANSGENE | CASH, KAILEY ELIZABETH | 1683 | §101§102§103§112DP | Non-Final OA | — | Pending | May 31, 2023 |
| 17996276 | USE OF AN ORPHAN MOTIF TO INCREASE EXPRESSION OF A HETEROLOGOUS TRANSGENE | HAMMELL, NEIL P | 1681 | §102DP | Non-Final OA | — | Pending | Oct 14, 2022 |
| 17756106 | PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN AGMAT-POSITIVE CELLS IN LAYER 2/3 OF MOUSE CORTEX | HILL, KEVIN KAI | 1638 | §102§103§112 | Final Rejection | 141d overdue | Pending | May 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFriedrich Miescher Institute For Biomedical Research has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Matasha Dhar has the most, with 1 of Friedrich Miescher Institute For Biomedical Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
